Inhibitors of HDACs - Effective drugs against cancer?

Current Cancer Drug Targets

Volumn 10, Issue 2, 2010, Pages 210-228

  Muller S ^a   Kramer O H ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cancer; Chemotherapy; Gene expression; Histone deacetylase; Histone deacetylase inhibitor; SAHA; Translational research; VPA

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; ATRAZINE; AZATHIOPRINE; BELINOSTAT; DEPSIPEPTIDE; DOXORUBICIN; EPIRUBICIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; RETINOIC ACID; THEOPHYLLINE; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CATALYSIS; CELL CYCLE ARREST; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE REPRESSION; GLIOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; MELANOMA; MESOTHELIOMA; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE TUMOR; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 77950640292     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791054149     Document Type: Article

References (155)

1. Phillips, D. M. The presence of acetyl groups of histones. Biochem. J. 1963, 87, 258-263.
2. Allfrey, V. G.; Faulkner, R.; Mirsky, A. E. Acetylation and methylation of histones and their possible role in the regulation of rna synthesis. Proc. Natl. Acad. Sci. USA 1964, 51, 786-794.
3. Inoue, A.; Fujimoto, D. Enzymatic deacetylation of histone. Biochem. Biophys. Res. Commun. 1969, 36, 146-150.
4. Turner, B. M. Defining an epigenetic code. Nat. Cell Biol. 2007, 9, 2-6.
5. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38-51.
6. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5, 37-50.
7. Yang, X. J.; Seto, E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 2008, 9, 206-218.
8. Spange, S.; Wagner, T.; Heinzel, T.; Krämer, O. H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 20090, 41(1), 185-198.
9. Krämer, O. H.; Göttlicher, M.; Heinzel, T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 2001, 12, 294-300.
10. Brandl, A.; Heinzel, T.; Kramer, O. H. Histone deacetylases: salesmen and customers in the post-translational modification market. Biol. Cell 2009, 101, 193-205.
11. Zhu, P.; Martin, E.; Mengwasser, J.; Schlag, P.; Janssen, K. P.; Göttlicher, M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5, 455-463.
12. Heinzel, T.; Krämer, O. H. Pharmacodynamic markers for histone deacetylase inhibitor development. Drug Discov. Today 2008, 4, 277-283.
13. Weichert, W.; Roske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; Fritzsche, F. R.; Niesporek, S.; Denkert, C.; Dietel, M.; Kristiansen, G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 2008, 98, 604-610.
14. Weichert, W.; Denkert, C.; Noske, A.; Darb-Esfahani, S.; Dietel, M.; Kalloger, S. E.; Huntsman, D. G.; Kobel, M. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008, 10, 1021-1027.
15. Krämer, O. H. HDAC2: a critical factor in health and disease. Trends Pharmacol. Sci. 2009, 30, 647-655.
16. Fritsche, P.; Seidler, B.; Schüler, S.; Schnieke, A.; Göttlicher, M.; Schmid, R. M.; Saur, D.; Schneider, G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009, 58, 1399-1409.
17. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5, 769-784.
18. Buchwald, M.; Krämer, O. H.; Heinzel, T. HDACi - targets beyond chromatin. Cancer Lett. 2009, 280, 160-167.
19. Lee, K. K.; Workman, J. L. Histone acetyltransferase complexes: one size doesn't fit all. Nat. Rev. Mol. Cell Biol. 2007, 8, 284-295.
20. Denu, J. M. The Sir 2 family of protein deacetylases. Curr. Opin. Chem. Biol. 2005, 9, 431-440.
21. Haigis, M. C.; Guarente, L. P. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20, 2913-2921.
22. Marmorstein, R.; Roth, S. Y. Histone acetyltransferases: function, structure, and catalysis. Curr. Opin. Genet. Dev. 2001, 11, 155-161.
23. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9, 3-16.
24. Chang, H. H.; Chiang, C. P.; Hung, H. C.; Lin, C. Y.; Deng, Y. T.; Kuo, M. Y. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 2009, 45(7), 610-614.
25. Khanim, F. L.; Bradbury, C. A.; Arrazi, J.; Hayden, R. E.; Rye, A.; Basu, S.; MacWhannell, A.; Sawers, A.; Griffiths, M.; Cook, M.; Freeman, S.; Nightingale, K. P.; Grimwade, D.; Falciani, F.; Turner, B. M.; Bunce, C. M.; Craddock, C. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br. J. Haematol. 2009, 144, 332-341.
26. Münster, P.; Marchion, D.; Bicaku, E.; Lacevic, M.; Kim, J.; Centeno, B.; Daud, A.; Neuger, A.; Minton, S.; Sullivan, D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer Res. 2009, 15, 2488-2496.
27. Münster, P. N.; Marchion, D.; Thomas, S.; Egorin, M.; Minton, S.; Springett, G.; Lee, J. H.; Simon, G.; Chiappori, A.; Sullivan, D.; Daud, A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer 2009, 101, 1044-1050.
28. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
29. Göttlicher, M.; Minucci, S.; Zhu, P.; Krämer, O. H.; Schimpf, A.; Giavara, S.; Sleeman, J. P.; Lo Coco, F.; Nervi, C.; Pelicci, P. G.; Heinzel, T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20, 6969-6978.
30. Krämer, O. H.; Zhu, P.; Ostendorff, H. P.; Golebiewski, M.; Tiefenbach, J.; Peters, M. A.; Brill, B.; Groner, B.; Bach, I.; Heinzel, T.; Göttlicher, M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003, 22, 3411-3420.
31. Gurvich, N.; Tsygankova, O. M.; Meinkoth, J. L.; Klein, P. S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 2004, 64, 1079-1086.
32. Marks, P. A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26, 1351-1356.
33. Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26, 5541-5552.
34. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 2003, 46, 5097-5116.
35. Hess-Stumpp, H.; Bracker, T. U.; Henderson, D.; Politz, O. MS-275, a potent orally available inhibitor of histone deacetylases - the development of an anticancer agent. Int. J. Biochem. Cell Biol. 2007, 39, 1388-1405.
36. Fournel, M.; Bonfils, C.; Hou, Y.; Yan, P. T.; Trachy-Bourget, M. C.; Kalita, A.; Liu, J.; Lu, A. H.; Zhou, N. Z.; Robert, M. F.; Gillespie, J.; Wang, J. J.; Ste-Croix, H.; Rahil, J.; Lefebvre, S.; Moradei, O.; Delorme, D.; Macleod, A. R.; Besterman, J. M.; Li, Z. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 2008, 7, 759-768.
37. Moradei, O.; Vaisburg, A.; Martell, R. E. Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. Curr. Top. Med. Chem. 2008, 8, 841-858.
38. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K. H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002, 62, 4916-4921.
39. Crabb, S. J.; Howell, M.; Rogers, H.; Ishfaq, M.; Yurek-George, A.; Carey, K.; Pickering, B. M.; East, P.; Mitter, R.; Maeda, S.; Johnson, P. W.; Townsend, P.; Shin-ya, K.; Yoshida, M.; Ganesan, A.; Packham, G. Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochem. Pharmacol. 2008, 76, 463-475.
40. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.; Mills, E.; Berghs, S. C.; Carey, N.; Finn, P. W.; Collins, L. S.; Tumber, A.; Ritchie, J. W.; Jensen, P. B.; Lichenstein, H. S.; Sehested, M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409, 581-589.
41. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 2003, 100, 4389-4394.
42. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
43. Codd, R.; Braich, N.; Liu, J.; Soe, C. Z.; Pakchung, A. A. Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilide hydroxamic acid and trichostatin A. Int. J. Biochem. Cell Biol. 2009, 41(4), 736-739.
44. Bieliauskas, A. V.; Pflum, M. K. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 2008, 37, 1402-1413.
45. Dehmel, F.; Ciossek, T.; Maier, T.; Weinbrenner, S.; Schmidt, B.; Zoche, M.; Beckers, T. Trithiocarbonates: exploration of a new head group for HDAC inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4746-4752.
46. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B. C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12, 1325-1334.
47. Wang, D. F.; Helquist, P.; Wiech, N. L.; Wiest, O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 2005, 48, 6936-6947.
48. Gantt, S. L.; Gattis, S. G.; Fierke, C. A. Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 2006, 45, 6170-6178.
49. Karagiannis, T. C.; El-Osta, A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007, 21, 61-65.
50. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J. J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008, 22, 1026-1034.
51. Carew, J. S.; Giles, F. J.; Nawrocki, S. T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269, 7-17.
52. Schrump, D. S. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res. 2009, 15, 3947-3957.
53. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27, 5459-5468.
54. Glaser, K. B.; Staver, M. J.; Waring, J. F.; Stender, J.; Ulrich, R. G.; Davidsen, S. K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2003, 2, 151-163.
55. Van Lint, C.; Emiliani, S.; Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996, 5, 245-253.
56. Moreira, J. M.; Scheipers, P.; Sorensen, P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 2003, 3, 30.
57. Trus, M. R.; Yang, L.; Suarez Saiz, F.; Bordeleau, L.; Jurisica, I.; Minden, M. D. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005, 19, 1161-1168.
58. Hoshino, I.; Matsubara, H.; Akutsu, Y.; Nishimori, T.; Yoneyama, Y.; Murakami, K.; Komatsu, A.; Sakata, H.; Matsushita, K.; Ochiai, T. Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells. Oncol. Rep. 2007, 18, 585-592.
59. Ellis, L.; Pan, Y.; Smyth, G. K.; George, D. J.; McCormack, C.; Williams-Truax, R.; Mita, M.; Beck, J.; Burris, H.; Ryan, G.; Atadja, P.; Butterfoss, D.; Dugan, M.; Culver, K.; Johnstone, R. W.; Prince, H. M. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res. 2008, 14, 4500-4510.
60. Caron, C.; Boyault, C.; Khochbin, S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 2005, 27, 408-415.
61. Glozak, M. A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363, 15-23.
62. Krämer, O. H.; Baus, D.; Knauer, S. K.; Stein, S.; Jäger, E.; Stauber, R. H.; Grez, M.; Pfitzner, E.; Heinzel, T. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 2006, 20, 473-485.
63. Glauben, R.; Sonnenberg, E.; Zeitz, M.; Siegmund, B. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett. 2009, 280, 154-159.
64. Kaler, P.; Sasazuki, T.; Shirasawa, S.; Augenlicht, L.; Klampfer, L. HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity. Exp. Cell Res. 2008, 314, 1507-1518.
65. Mitsiades, N.; Mitsiades, C. S.; Richardson, P. G.; McMullan, C.; Poulaki, V.; Fanourakis, G.; Schlossman, R.; Chauhan, D.; Munshi, N. C.; Hideshima, T.; Richon, V. M.; Marks, P. A.; Anderson, K. C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101, 4055-4062.
66. Mitsiades, C. S.; Mitsiades, N. S.; McMullan, C. J.; Poulaki, V.; Shringarpure, R.; Hideshima, T.; Akiyama, M.; Chauhan, D.; Munshi, N.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T. A.; Richon, V. M.; Marks, P. A.; Anderson, K. C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA 2004, 101, 540-545.
67. Imre, G.; Gekeler, V.; Leja, A.; Beckers, T.; Boehm, M. Histone deacetylase inhibitors suppress the inducibility of nuclear factorkappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res. 2006, 66, 5409-5418.
68. Lehmann, A.; Denkert, C.; Budczies, J.; Buckendahl, A. C.; Darb-Esfahani, S.; Noske, A.; Muller, B. M.; Bahra, M.; Neuhaus, P.; Dietel, M.; Kristiansen, G.; Weichert, W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009, 9, 395.
69. Tou, L.; Liu, Q.; Shivdasani, R. A. Regulation of mammalian epithelial differentiation and intestine development by class I histone deacetylases. Mol. Cell Biol. 2004, 24, 3132-3139.
70. Bug, G.; Ritter, M.; Wassmann, B.; Schoch, C.; Heinzel, T.; Schwarz, K.; Romanski, A.; Krämer, O. H.; Kampfmann, M.; Hoelzer, D.; Neubauer, A.; Ruthardt, M.; Ottmann, O. G. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104, 2717-2725.
71. Hrzenjak, A.; Moinfar, F.; Kremser, M. L.; Strohmeier, B.; Staber, P. B.; Zatloukal, K.; Denk, H. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 2006, 5, 2203-2210.
72. Atmaca, A.; Al-Batran, S. E.; Maurer, A.; Neumann, A.; Heinzel, T.; Hentsch, B.; Schwarz, S. E.; Hövelmann, S.; Gottlicher, M.; Knuth, A.; Jäger, E. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br. J. Cancer 2007, 97, 177-182.
73. Yang, G.; Thompson, M. A.; Brandt, S. J.; Hiebert, S. W. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 2007, 26, 91-101.
74. Krämer, O. H.; Müller, S.; Buchwald, M.; Reichardt, S.; Heinzel, T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RAR{alpha}. FASEB J. 2008, 22(5), 1369-1379.
75. Tabe, Y.; Konopleva, M.; Kondo, Y.; Contractor, R.; Jin, L.; Ruvolo, V.; Tsutsumi-Ishii, Y.; Miyake, K.; Miyake, N.; Ohsaka, A.; Nagaoka, I.; Issa, J. P.; Andreeff, M. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Ann. Hematol. 2006, 85, 689-704.
76. Blum, K. A.; Advani, A.; Fernandez, L.; Van Der Jagt, R.; Brandwein, J.; Kambhampati, S.; Kassis, J.; Davis, M.; Bonfils, C.; Dubay, M.; Dumouchel, J.; Drouin, M.; Lucas, D. M.; Martell, R. E.; Byrd, J. C. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br. J. Haematol. 2009, 147, 507-514.
77. Ramalingam, S. S.; Belani, C. P.; Ruel, C.; Frankel, P.; Gitlitz, B.; Koczywas, M.; Espinoza-Delgado, I.; Gandara, D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J. Thorac. Oncol. 2009, 4, 97-101.
78. Elaut, G.; Rogiers, V.; Vanhaecke, T. The pharmaceutical potential of histone deacetylase inhibitors. Curr. Pharm. Des. 2007, 13, 2584-2620.
79. Byrd, J. C.; Marcucci, G.; Parthun, M. R.; Xiao, J. J.; Klisovic, R. B.; Moran, M.; Lin, T. S.; Liu, S.; Sklenar, A. R.; Davis, M. E.; Lucas, D. M.; Fischer, B.; Shank, R.; Tejaswi, S. L.; Binkley, P.; Wright, J.; Chan, K. K.; Grever, M. R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105, 959-967.
80. Shah, M. H.; Binkley, P.; Chan, K.; Xiao, J.; Arbogast, D.; Collamore, M.; Farra, Y.; Young, D.; Grever, M. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 2006, 12, 3997-4003.
81. Molife, R.; Fong, P.; Scurr, M.; Judson, I.; Kaye, S.; de Bono, J. HDAC inhibitors and cardiac safety. Clin. Cancer Res. 2007, 13, 1068; author reply 1068-1069.
82. Woyach, J. A.; Kloos, R. T.; Ringel, M. D.; Arbogast, D.; Collamore, M.; Zwiebel, J. A.; Grever, M.; Villalona-Calero, M.; Shah, M. H. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J. Clin. Endocrinol. Metab. 2009, 94, 164-170.
83. Bradbury, C. A.; Khanim, F. L.; Hayden, R.; Bunce, C. M.; White, D. A.; Drayson, M. T.; Craddock, C.; Turner, B. M. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19, 1751-1759.
84. Lucio-Eterovic, A. K.; Cortez, M. A.; Valera, E. T.; Motta, F. J.; Queiroz, R. G.; Machado, H. R.; Carlotti, C. G., Jr.; Neder, L.; Scrideli, C. A.; Tone, L. G. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008, 8, 243.
85. Menegola, E.; Di Renzo, F.; Broccia, M. L.; Giavini, E. Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Res. C Embryo Today 2006, 78, 345-353.
86. Hallas, J.; Friis, S.; Bjerrum, L.; Stovring, H.; Narverud, S. F.; Heyerdahl, T.; Gronbaek, K.; Andersen, M. Cancer risk in longterm users of valproate: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1714-1719.
87. Dejligbjerg, M.; Grauslund, M.; Christensen, I. J.; Tjornelund, J.; Buhl Jensen, P.; Sehested, M. Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark. 2008, 4, 101-109.
88. Zhang, X.; Zhang, L.; Yang, H.; Huang, X.; Otu, H.; Libermann, T. A.; DeWolf, W. C.; Khosravi-Far, R.; Olumi, A. F. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 2007, 67, 9425-9434.
89. Fulda, S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 2008, 8, 132-140.
90. Verde, P.; Casalino, L.; Talotta, F.; Yaniv, M.; Weitzman, J. B. Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle 2007, 6, 2633-2639.
91. Schrell, U. M.; Rittig, M. G.; Anders, M.; Kiesewetter, F.; Marschalek, R.; Koch, U. H.; Fahlbusch, R. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J. Neurosurg. 1997, 86, 845-852.
92. Montefusco, E.; Fazi, F.; Cordone, I.; Ariola, C.; Nanni, M.; Spadea, A.; Spiriti, M. A.; Fenu, S.; Mandelli, F.; Petti, M. C. Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma. Leuk. Lymphoma 2001, 40, 671-674.
93. Shao, J.; Zhou, B.; Chu, B.; Yen, Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 2006, 6, 409-431.
94. Krämer, O. H.; Knauer, S. K.; Zimmermann, D.; Stauber, R. H.; Heinzel, T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 2008, 27, 732-740.
95. Burgess, A. J.; Pavey, S.; Warrener, R.; Hunter, L. J.; Piva, T. J.; Musgrove, E. A.; Saunders, N.; Parsons, P. G.; Gabrielli, B. G. Upregulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 2001, 60, 828-837.
96. Rosato, R. R.; Almenara, J. A.; Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003, 63, 3637-3645.
97. Nguyen, D. M.; Schrump, W. D.; Chen, G. A.; Tsai, W.; Nguyen, P.; Trepel, J. B.; Schrump, D. S. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin. Cancer Res. 2004, 10, 1813-1825.
98. Bracarda, S.; Eggermont, A. M.; Samuelsson, J. Redefining the role of interferon in the treatment of malignant diseases. Eur. J. Cancer 2009.
99. Krämer, O. H.; Heinzel, T. Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol. Cell Endocrinol. 2010, 315(1-2), 40-48.
100. Klampfer, L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets 2006, 6, 107-121.
101. Klampfer, L.; Huang, J.; Swaby, L. A.; Augenlicht, L. Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 2004, 279, 30358-30368.
102. Rocca, A.; Minucci, S.; Tosti, G.; Croci, D.; Contegno, F.; Ballarini, M.; Nole, F.; Munzone, E.; Salmaggi, A.; Goldhirsch, A.; Pelicci, P. G.; Testori, A. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br. J. Cancer 2009, 100, 28-36.
103. Robey, R. W.; Zhan, Z.; Piekarz, R. L.; Kayastha, G. L.; Fojo, T.; Bates, S. E. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin. Cancer Res. 2006, 12, 1547-1555.
104. Fedier, A.; Dedes, K. J.; Imesch, P.; Von Bueren, A. O.; Fink, D. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int. J. Oncol. 2007, 31, 633-641.
105. Griffiths, E. A.; Gore, S. D. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin. Hematol. 2008, 45, 23-30.
106. Gore, S. D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C. B.; Carducci, M.; Grever, M.; Galm, O.; Dauses, T.; Karp, J. E.; Rudek, M. A.; Zhao, M.; Smith, B. D.; Manning, J.; Jiemjit, A.; Dover, G.; Mays, A.; Zwiebel, J.; Murgo, A.; Weng, L. J.; Herman, J. G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006, 66, 6361-6369.
107. Garcia-Manero, G.; Kantarjian, H. M.; Sanchez-Gonzalez, B.; Yang, H.; Rosner, G.; Verstovsek, S.; Rytting, M.; Wierda, W. G.; Ravandi, F.; Koller, C.; Xiao, L.; Faderl, S.; Estrov, Z.; Cortes, J.; O'Brien, S.; Estey, E.; Bueso-Ramos, C.; Fiorentino, J.; Jabbour, E.; Issa, J. P. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108, 3271-3279.
108. Blum, W.; Klisovic, R. B.; Hackanson, B.; Liu, Z.; Liu, S.; Devine, H.; Vukosavljevic, T.; Huynh, L.; Lozanski, G.; Kefauver, C.; Plass, C.; Devine, S. M.; Heerema, N. A.; Murgo, A.; Chan, K. K.; Grever, M. R.; Byrd, J. C.; Marcucci, G. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol. 2007, 25, 3884-3891.
109. Münster, P.; Marchion, D.; Bicaku, E.; Schmitt, M.; Lee, J. H.; DeConti, R.; Simon, G.; Fishman, M.; Minton, S.; Garrett, C.; Chiappori, A.; Lush, R.; Sullivan, D.; Daud, A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol. 2007, 25, 1979-1985.
110. Masoudi, A.; Elopre, M.; Amini, E.; Nagel, M. E.; Ater, J. L.; Gopalakrishnan, V.; Wolff, J. E. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008, 28, 2437-2442.
111. Karagiannis, T. C.; Kn, H.; El-Osta, A. The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 2006, 1, 131-137.
112. Frew, A. J.; Johnstone, R. W.; Bolden, J. E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009, 280, 125-133.
113. Kuendgen, A.; Schmid, M.; Schlenk, R.; Knipp, S.; Hildebrandt, B.; Steidl, C.; Germing, U.; Haas, R.; Dohner, H.; Gattermann, N. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106, 112-119.
114. Burgess, A.; Ruefli, A.; Beamish, H.; Warrener, R.; Saunders, N.; Johnstone, R.; Gabrielli, B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004, 23, 6693-6701.
115. Tang, R.; Faussat, A. M.; Majdak, P.; Perrot, J. Y.; Chaoui, D.; Legrand, O.; Marie, J. P. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004, 18, 1246-1251.
116. Blaheta, R. A.; Cinatl, J., Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev. 2002, 22, 492-511.
117. Blaheta, R. A.; Michaelis, M.; Driever, P. H.; Cinatl, J., Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med. Res. Rev. 2005, 25, 383-397.
118. Kuendgen, A.; Gattermann, N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110, 943-954.
119. Chen, J. S.; Faller, D. V.; Spanjaard, R. A. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr. Cancer Drug Targets 2003, 3, 219-236.
120. Warrell, R. P., Jr.; He, L. Z.; Richon, V.; Calleja, E.; Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 1998, 90, 1621-1625.
121. Gore, S. D.; Weng, L. J.; Figg, W. D.; Zhai, S.; Donehower, R. C.; Dover, G.; Grever, M. R.; Griffin, C.; Grochow, L. B.; Hawkins, A.; Burks, K.; Zabelena, Y.; Miller, C. B. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 2002, 8, 963-970.
122. Phiel, C. J.; Zhang, F.; Huang, E. Y.; Guenther, M. G.; Lazar, M. A.; Klein, P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001, 276, 36734-36741.
123. McMullin, M. F.; Nugent, E.; Thompson, A.; Hull, D.; Jones, F. G.; Grimwade, D. Prolonged molecular remission in PMLRARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate. Leukemia 2005, 19, 1676-1677.
124. Kuendgen, A.; Strupp, C.; Aivado, M.; Bernhardt, A.; Hildebrandt, B.; Haas, R.; Germing, U.; Gattermann, N. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004, 104, 1266-1269.
125. Cimino, G.; Lo-Coco, F.; Fenu, S.; Travaglini, L.; Finolezzi, E.; Mancini, M.; Nanni, M.; Careddu, A.; Fazi, F.; Padula, F.; Fiorini, R.; Spiriti, M. A.; Petti, M. C.; Venditti, A.; Amadori, S.; Mandelli, F.; Pelicci, P. G.; Nervi, C. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res. 2006, 66, 8903-8911.
126. Kuendgen, A.; Knipp, S.; Fox, F.; Strupp, C.; Hildebrandt, B.; Steidl, C.; Germing, U.; Haas, R.; Gattermann, N. Results of a phase 2 study of valproic acid alone or in combination with alltrans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann. Hematol. 2005, 84(Suppl 1), 61-66.
127. Soriano, A. O.; Yang, H.; Faderl, S.; Estrov, Z.; Giles, F.; Ravandi, F.; Cortes, J.; Wierda, W. G.; Ouzounian, S.; Quezada, A.; Pierce, S.; Estey, E. H.; Issa, J. P.; Kantarjian, H. M.; Garcia-Manero, G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110, 2302-2308.
128. Braiteh, F.; Soriano, A. O.; Garcia-Manero, G.; Hong, D.; Johnson, M. M.; Silva Lde, P.; Yang, H.; Alexander, S.; Wolff, J.; Kurzrock, R. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res. 2008, 14, 6296-6301.
129. Candelaria, M.; Gallardo-Rincon, D.; Arce, C.; Cetina, L.; Aguilar-Ponce, J. L.; Arrieta, O.; Gonzalez-Fierro, A.; Chavez-Blanco, A.; de la Cruz-Hernandez, E.; Camargo, M. F.; Trejo-Becerril, C.; Perez-Cardenas, E.; Perez-Plasencia, C.; Taja-Chayeb, L.; Wegman-Ostrosky, T.; Revilla-Vazquez, A.; Duenas-Gonzalez, A. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol. 2007, 18, 1529-1538.
130. Ryan, Q. C.; Headlee, D.; Acharya, M.; Sparreboom, A.; Trepel, J. B.; Ye, J.; Figg, W. D.; Hwang, K.; Chung, E. J.; Murgo, A.; Melillo, G.; Elsayed, Y.; Monga, M.; Kalnitskiy, M.; Zwiebel, J.; Sausville, E. A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005, 23, 3912-3922.
131. Gore, L.; Rothenberg, M. L.; O'Bryant, C. L.; Schultz, M. K.; Sandler, A. B.; Coffin, D.; McCoy, C.; Schott, A.; Scholz, C.; Eckhardt, S. G. A phase I and pharmacokinetic study of the oral his tone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 2008, 14, 4517-4525.
132. Gojo, I.; Jiemjit, A.; Trepel, J. B.; Sparreboom, A.; Figg, W. D.; Rollins, S.; Tidwell, M. L.; Greer, J.; Chung, E. J.; Lee, M. J.; Gore, S. D.; Sausville, E. A.; Zwiebel, J.; Karp, J. E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109, 2781-2790.
133. Hauschild, A.; Trefzer, U.; Garbe, C.; Kaehler, K. C.; Ugurel, S.; Kiecker, F.; Eigentler, T.; Krissel, H.; Schott, A.; Schadendorf, D. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2- aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 2008, 18, 274-278.
134. Garcia-Manero, G.; Assouline, S.; Cortes, J.; Estrov, Z.; Kantarjian, H.; Yang, H.; Newsome, W. M.; Miller, W. H., Jr.; Rousseau, C.; Kalita, A.; Bonfils, C.; Dubay, M.; Patterson, T. A.; Li, Z.; Besterman, J. M.; Reid, G.; Laille, E.; Martell, R. E.; Minden, M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112, 981-989.
135. Siu, L. L.; Pili, R.; Duran, I.; Messersmith, W. A.; Chen, E. X.; Sullivan, R.; MacLean, M.; King, S.; Brown, S.; Reid, G. K.; Li, Z.; Kalita, A. M.; Laille, E. J.; Besterman, J. M.; Martell, R. E.; Carducci, M. A. Phase I study of MGCD0103 given as a threetimes-per-week oral dose in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26, 1940-1947.
136. Le Tourneau, C.; Siu, L. L. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. Expert Opin Investig. Drugs 2008, 17, 1247-1254.
137. Piekarz, R. L.; Robey, R.; Sandor, V.; Bakke, S.; Wilson, W. H.; Dahmoush, L.; Kingma, D. M.; Turner, M. L.; Altemus, R.; Bates, S. E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001, 98, 2865-2868.
138. Shao, R. H.; Tian, X.; Gorgun, G.; Urbano, A. G.; Foss, F. M. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leuk. Res. 2002, 26, 1077-1083.
139. Odenike, O. M.; Alkan, S.; Sher, D.; Godwin, J. E.; Huo, D.; Brandt, S. J.; Green, M.; Xie, J.; Zhang, Y.; Vesole, D. H.; Stiff, P.; Wright, J.; Larson, R. A.; Stock, W. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin. Cancer Res. 2008, 14, 7095-7101.
140. Zhang, C. L.; McKinsey, T. A.; Chang, S.; Antos, C. L.; Hill, J. A.; Olson, E. N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110, 479-488.
141. Trivedi, C. M.; Luo, Y.; Yin, Z.; Zhang, M.; Zhu, W.; Wang, T.; Floss, T.; Goettlicher, M.; Noppinger, P. R.; Wurst, W.; Ferrari, V. A.; Abrams, C. S.; Gruber, P. J.; Epstein, J. A. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat. Med. 2007, 13, 324-331.
142. Kelly, W. K.; O'Connor, O. A.; Krug, L. M.; Chiao, J. H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J. P.; Schwartz, L.; Richardson, S.; Chu, E.; Olgac, S.; Marks, P. A.; Scher, H.; Richon, V. M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 3923-3931.
143. Kelly, W. K.; Richon, V. M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J. H.; Rifkind, R.; Marks, P. A.; Scher, H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003, 9, 3578-3588.
144. Duvic, M.; Talpur, R.; Ni, X.; Zhang, C.; Hazarika, P.; Kelly, C.; Chiao, J. H.; Reilly, J. F.; Ricker, J. L.; Richon, V. M.; Frankel, S. R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109, 31-39.
145. Olsen, E. A.; Kim, Y. H.; Kuzel, T. M.; Pacheco, T. R.; Foss, F. M.; Parker, S.; Frankel, S. R.; Chen, C.; Ricker, J. L.; Arduino, J. M.; Duvic, M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 2007, 25, 3109-3115.
146. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12, 1247-1252.
147. Garcia-Manero, G.; Yang, H.; Bueso-Ramos, C.; Ferrajoli, A.; Cortes, J.; Wierda, W. G.; Faderl, S.; Koller, C.; Morris, G.; Rosner, G.; Loboda, A.; Fantin, V. R.; Randolph, S. S.; Hardwick, J. S.; Reilly, J. F.; Chen, C.; Ricker, J. L.; Secrist, J. P.; Richon, V. M.; Frankel, S. R.; Kantarjian, H. M. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111, 1060-1066.
148. Richardson, P.; Mitsiades, C.; Colson, K.; Reilly, E.; McBride, L.; Chiao, J.; Sun, L.; Ricker, J.; Rizvi, S.; Oerth, C.; Atkins, B.; Fearen, I.; Anderson, K.; Siegel, D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma 2008, 49, 502-507.
149. Blumenschein, G. R., Jr.; Kies, M. S.; Papadimitrakopoulou, V. A.; Lu, C.; Kumar, A. J.; Ricker, J. L.; Chiao, J. H.; Chen, C.; Frankel, S. R. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. New Drugs 2008, 26, 81-87.
150. Krug, L. M.; Curley, T.; Schwartz, L.; Richardson, S.; Marks, P.; Chiao, J.; Kelly, W. K. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin. Lung Cancer 2006, 7, 257-261.
151. Giles, F.; Fischer, T.; Cortes, J.; Garcia-Manero, G.; Beck, J.; Ravandi, F.; Masson, E.; Rae, P.; Laird, G.; Sharma, S.; Kantarjian, H.; Dugan, M.; Albitar, M.; Bhalla, K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 2006, 12, 4628-4635.
152. Plumb, J. A.; Finn, P. W.; Williams, R. J.; Bandara, M. J.; Romero, M. R.; Watkins, C. J.; La Thangue, N. B.; Brown, R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2003, 2, 721-728.
153. Steele, N. L.; Plumb, J. A.; Vidal, L.; Tjornelund, J.; Knoblauch, P.; Rasmussen, A.; Ooi, C. E.; Buhl-Jensen, P.; Brown, R.; Evans, T. R.; DeBono, J. S. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 804-810.
154. Gimsing, P.; Hansen, M.; Knudsen, L. M.; Knoblauch, P.; Christensen, I. J.; Ooi, C. E.; Buhl-Jensen, P. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 2008, 81, 170-176.
155. Maslak, P.; Chanel, S.; Camacho, L. H.; Soignet, S.; Pandolfi, P. P.; Guernah, I.; Warrell, R.; Nimer, S. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2006, 20, 212-217.